If, as our data suggest, DKK1 expression can be modulated by a SERM and the glycoprotein contributes to metastatic progression, then this study has revealed a new therapeutic axis that can be exploited to treat endocrine-resistant ESR1 mutant breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.